- Home
- NIVF vs ADTX Comparison
NIVF vs ADTX Comparison
Compare NIVF & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- ADTX
- Stock Information
- Founded
- NIVF 2011
- ADTX 2017
- Country
- NIVF Hong Kong
- ADTX United States
- Employees
- NIVF N/A
- ADTX N/A
- Industry
- NIVF
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- NIVF
- ADTX Health Care
- Exchange
- NIVF NYSE
- ADTX Nasdaq
- Market Cap
- NIVF 5.2M
- ADTX 5.3M
- IPO Year
- NIVF N/A
- ADTX 2020
- Fundamental
- Price
- NIVF $0.35
- ADTX $0.21
- Analyst Decision
- NIVF
- ADTX
- Analyst Count
- NIVF 0
- ADTX 0
- Target Price
- NIVF N/A
- ADTX N/A
- AVG Volume (30 Days)
- NIVF 6.4M
- ADTX 1.7M
- Earning Date
- NIVF 02-16-2025
- ADTX 11-18-2024
- Dividend Yield
- NIVF N/A
- ADTX N/A
- EPS Growth
- NIVF N/A
- ADTX N/A
- EPS
- NIVF N/A
- ADTX N/A
- Revenue
- NIVF $5,679,218.00
- ADTX $212,107.00
- Revenue This Year
- NIVF N/A
- ADTX $95.61
- Revenue Next Year
- NIVF N/A
- ADTX $1,584.79
- P/E Ratio
- NIVF N/A
- ADTX N/A
- Revenue Growth
- NIVF N/A
- ADTX N/A
- 52 Week Low
- NIVF $0.24
- ADTX $0.19
- 52 Week High
- NIVF $17.24
- ADTX $338.80
- Technical
- Relative Strength Index (RSI)
- NIVF 44.71
- ADTX 19.37
- Support Level
- NIVF $0.30
- ADTX $0.19
- Resistance Level
- NIVF $0.43
- ADTX $0.39
- Average True Range (ATR)
- NIVF 0.08
- ADTX 0.03
- MACD
- NIVF 0.01
- ADTX 0.09
- Stochastic Oscillator
- NIVF 45.05
- ADTX 13.74
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.